Acadian Asset Management LLC Catalyst Biosciences, Inc. Transaction History

Acadian Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.33 - $0.65 $26,477 - $52,152	-80,235 Reduced 55.71%	63,793 $30,000
Q2 2023 Aug 07, 2023	SELL	$0.2 - $0.35 $23,087 - $40,403	-115,439 Reduced 44.49%	144,028 $50,000
Q1 2023 May 11, 2023	BUY	$0.19 - $0.64 $49,298 - $166,058	259,467 New	259,467 $52,000
Q2 2022 Aug 09, 2022	SELL	$0.36 - $1.78 $40,668 - $201,083	-112,968 Reduced 95.1%	5,821 $10,000
Q1 2022 May 12, 2022	SELL	$0.51 - $1.0 $57,941 - $113,611	-113,611 Reduced 48.89%	118,789 $77,000
Q4 2021 Feb 10, 2022	BUY	$0.91 - $4.16 $211,484 - $966,784	232,400 New	232,400 $211,000
Q2 2019 Aug 08, 2019	SELL	$7.08 - $10.6 $417,394 - $624,912	-58,954 Closed	0 $0
Q1 2019 May 09, 2019	SELL	$7.67 - $9.96 $403,296 - $523,706	-52,581 Reduced 47.14%	58,954 $478,000
Q4 2018 Feb 07, 2019	SELL	$6.59 - $11.28 $356,637 - $610,451	-54,118 Reduced 32.67%	111,535 $880,000
Q3 2018 Oct 30, 2018	BUY	$9.35 - $12.44 $566,750 - $754,050	60,615 Added 57.71%	165,653 $1.79 Million
Q2 2018 Jul 24, 2018	BUY	$9.11 - $28.88 $956,896 - $3.03 Million	105,038 New	105,038 $1.23 Million

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.